vs
Side-by-side financial comparison of AMREP CORP. (AXR) and Invivyd, Inc. (IVVD). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $14.6M, roughly 1.2× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs -64.3%, a 85.9% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs 24.5%).
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
AXR vs IVVD — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.6M | $17.2M |
| Net Profit | $3.1M | $-11.1M |
| Gross Margin | — | — |
| Operating Margin | 20.6% | -73.0% |
| Net Margin | 21.6% | -64.3% |
| Revenue YoY | 93.8% | 24.5% |
| Net Profit YoY | 338.9% | 40.0% |
| EPS (diluted) | $0.58 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $17.2M | ||
| Q3 25 | $17.9M | $13.1M | ||
| Q2 25 | $11.2M | $11.8M | ||
| Q1 25 | $7.5M | $11.3M | ||
| Q4 24 | $11.9M | $13.8M | ||
| Q3 24 | $19.1M | $9.3M | ||
| Q2 24 | $19.5M | $2.3M |
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $-11.1M | ||
| Q3 25 | $4.7M | $-10.5M | ||
| Q2 25 | $3.9M | $-14.7M | ||
| Q1 25 | $717.0K | $-16.3M | ||
| Q4 24 | $4.0M | $-18.4M | ||
| Q3 24 | $4.1M | $-60.7M | ||
| Q2 24 | $4.1M | $-47.2M |
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | -73.0% | ||
| Q3 25 | 34.4% | -84.0% | ||
| Q2 25 | 31.7% | -127.8% | ||
| Q1 25 | 5.7% | -149.7% | ||
| Q4 24 | 26.4% | -139.1% | ||
| Q3 24 | 26.1% | -670.0% | ||
| Q2 24 | 23.9% | -2175.2% |
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | -64.3% | ||
| Q3 25 | 26.3% | -79.7% | ||
| Q2 25 | 34.8% | -124.4% | ||
| Q1 25 | 9.5% | -144.1% | ||
| Q4 24 | 33.9% | -133.5% | ||
| Q3 24 | 21.3% | -653.1% | ||
| Q2 24 | 21.2% | -2086.9% |
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $0.02 | ||
| Q3 25 | $0.87 | $-0.06 | ||
| Q2 25 | $0.73 | $-0.12 | ||
| Q1 25 | $0.13 | $-0.14 | ||
| Q4 24 | $0.75 | $-0.14 | ||
| Q3 24 | $0.76 | $-0.51 | ||
| Q2 24 | $0.77 | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.0M | $226.7M |
| Total DebtLower is stronger | $21.0K | — |
| Stockholders' EquityBook value | $139.4M | $241.5M |
| Total Assets | $143.9M | $276.9M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $226.7M | ||
| Q3 25 | $48.9M | $85.0M | ||
| Q2 25 | $39.5M | $34.9M | ||
| Q1 25 | $36.9M | $48.1M | ||
| Q4 24 | $40.1M | $69.3M | ||
| Q3 24 | $40.4M | $106.9M | ||
| Q2 24 | $29.7M | $147.9M |
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $35.0K | — |
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $241.5M | ||
| Q3 25 | $134.7M | $93.1M | ||
| Q2 25 | $130.0M | $42.8M | ||
| Q1 25 | $126.0M | $54.1M | ||
| Q4 24 | $125.1M | $67.5M | ||
| Q3 24 | $122.2M | $83.2M | ||
| Q2 24 | $118.0M | $140.6M |
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $276.9M | ||
| Q3 25 | $140.7M | $139.2M | ||
| Q2 25 | $133.8M | $89.1M | ||
| Q1 25 | $128.9M | $103.7M | ||
| Q4 24 | $129.1M | $129.5M | ||
| Q3 24 | $127.0M | $161.9M | ||
| Q2 24 | $122.8M | $177.3M |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.4M | $-15.5M |
| Free Cash FlowOCF − Capex | $5.4M | — |
| FCF MarginFCF / Revenue | 37.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $-15.5M | ||
| Q3 25 | $9.5M | $-8.3M | ||
| Q2 25 | $10.2M | $-13.3M | ||
| Q1 25 | $-3.2M | $-21.1M | ||
| Q4 24 | $-182.0K | $-37.6M | ||
| Q3 24 | $10.7M | $-41.1M | ||
| Q2 24 | $10.7M | $-41.6M |
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.7M | $-13.3M | ||
| Q1 25 | $-3.3M | $-21.3M | ||
| Q4 24 | $-268.0K | $-37.6M | ||
| Q3 24 | $10.7M | $-41.1M | ||
| Q2 24 | $10.3M | — |
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 86.4% | -112.9% | ||
| Q1 25 | -43.4% | -188.2% | ||
| Q4 24 | -2.3% | -272.2% | ||
| Q3 24 | 55.8% | -441.6% | ||
| Q2 24 | 52.5% | — |
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 5.2% | 0.1% | ||
| Q1 25 | 0.3% | 1.3% | ||
| Q4 24 | 0.7% | 0.0% | ||
| Q3 24 | 0.2% | 0.1% | ||
| Q2 24 | 2.3% | 0.0% |
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
